Skip to content
Article Rich – Lifestyle
Author:
Tenaya Therapeutics, Inc.
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 11, 2026
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
March 9, 2026
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
March 5, 2026
←
Previous Page
1
2